Nykredit A S bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 149,626 shares of the medical research company’s stock, valued at approximately $54,183,000.
Several other large investors also recently modified their holdings of the stock. Tranquilli Financial Advisor LLC raised its holdings in shares of Amgen by 5.6% in the 2nd quarter. Tranquilli Financial Advisor LLC now owns 829 shares of the medical research company’s stock worth $300,000 after purchasing an additional 44 shares during the period. MBA Advisors LLC grew its holdings in Amgen by 2.1% during the second quarter. MBA Advisors LLC now owns 3,168 shares of the medical research company’s stock valued at $1,147,000 after purchasing an additional 66 shares during the period. Birch Capital Management LLC increased its position in Amgen by 2.9% in the second quarter. Birch Capital Management LLC now owns 25,585 shares of the medical research company’s stock worth $9,265,000 after buying an additional 710 shares during the last quarter. PYA Waltman Capital LLC increased its position in Amgen by 29.0% in the second quarter. PYA Waltman Capital LLC now owns 17,735 shares of the medical research company’s stock worth $6,422,000 after buying an additional 3,983 shares during the last quarter. Finally, Beacon Financial Advisory LLC raised its stake in shares of Amgen by 2.0% in the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after buying an additional 25 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Wall Street Analysts Forecast Growth
AMGN has been the topic of a number of recent research reports. Robert W. Baird upped their price target on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 price objective on Amgen in a research note on Friday, June 5th. Canaccord Genuity Group upped their price objective on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Argus increased their target price on shares of Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. Finally, Sanford C. Bernstein lifted their target price on shares of Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $380.43.
Insider Activity
In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.
Amgen News Roundup
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: New evidence that Amgen’s cholesterol drug Repatha reduced the risk of death among patients at high risk of heart attack or stroke strengthens the drug’s clinical profile and could support broader use, sales growth and reimbursement. Amgen’s Repatha reduces risk of death in people at high risk of heart attack or stroke
- Positive Sentiment: Commentary highlighted Repatha’s potentially significant cardiovascular opportunity, adding to investor enthusiasm about a product that could become an important long-term growth driver beyond Amgen’s current results. Jim Cramer on Amgen’s cardiovascular opportunity
- Positive Sentiment: Analyst H. Engel of Erste Group raised the firm’s 2027 EPS estimate to $24.43 from $23.50, signaling improved expectations for Amgen’s earnings trajectory, although the firm maintained a Hold rating.
- Neutral Sentiment: Amgen will present at the Wells Fargo Healthcare Conference, giving investors a potential update on its pipeline, commercial outlook and strategy. The announcement itself contains no new financial guidance. Amgen to present at the 2026 Wells Fargo Healthcare Conference
- Negative Sentiment: U.K. regulators suspended Tavneos for new patients and halted its sale after determining that the main supporting study contained unreliable data. The action threatens sales of the rare-disease treatment and raises the risk of additional regulatory scrutiny or restrictions in other markets. UK regulator suspends Amgen’s Tavneos for new patients
Amgen Price Performance
Amgen stock opened at $442.84 on Thursday. The firm has a market capitalization of $239.41 billion, a P/E ratio of 27.52, a PEG ratio of 3.16 and a beta of 0.43. Amgen Inc. has a one year low of $269.77 and a one year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The business has a fifty day moving average price of $393.99 and a 200-day moving average price of $366.13.
Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.97 EPS for the current year.
Amgen Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s dividend payout ratio is currently 62.65%.
Amgen Profile
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Articles
- Five stocks we like better than Amgen
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
